Premium
Peroxisome proliferator‐activated receptor gamma in human prostate carcinoma
Author(s) -
Nakamura Yasuhiro,
Suzuki Takashi,
Sugawara Akira,
Arai Yoichi,
Sasano Hironobu
Publication year - 2009
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/j.1440-1827.2009.02367.x
Subject(s) - peroxisome proliferator activated receptor , nuclear receptor , prostate cancer , prostate , receptor , endocrinology , medicine , immunohistochemistry , biology , cancer research , peroxisome , cancer , transcription factor , biochemistry , gene
Peroxisome proliferator‐activated receptor (PPAR) is a member of the nuclear hormone receptor superfamily of transcription factors. Peroxisome proliferator‐activated receptor gamma (PPARγ) plays an important role in the regulation of lipid homeostasis, adipogenesis, insulin resistance, and development of various organs. Agonists of PPARγ have been also reported to inhibit proliferation of prostate carcinoma cells as in other human malignancies, and these synthetic ligands have been used in differentiation‐mediated therapy of various human carcinomas associated with high levels of PPARγ. The significance of PPARγ expression, however, was unknown in human prostate carcinoma tissues. The purpose of the present study was therefore to examine the immunolocalization of PPARγ in human prostate cancer tissues (40 cases) and correlate the findings with clinicopathological features of the patients in order to evaluate its possible biological significance. Twenty‐nine patients were positive for PPARγ immunoreactivity (73%) and a significant inverse correlation was detected between PPARγ immunoreactivity, pT stage ( P = 0.036), and serum concentration of prostate‐specific antigen ( P = 0.0004). In conclusion, PPARγ immunoreactivity is considered to be a new clinicopathological parameter of human prostate cancer.